X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CD14152 (nemolizumab) is a humanized anti-human IL-31 receptor A monoclonal antibody, which is being evaluated for the treatment of patients with prurigo nodularis & for adolescents and adults with moderate to severe atopic dermatitis.
Lead Product(s): Nemolizumab
Therapeutic Area: Dermatology Product Name: CD14152
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
QM1114-DP (relabotulinumtoxinA) is a botulinum toxin neuromodulator, which is under phase 3 clinical development for the treatment of glabellar frown lines & lateral canthal lines.
Lead Product(s): RelabotulinumtoxinA
Therapeutic Area: Dermatology Product Name: QM1114-DP
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
Through agreement, Nestlé Health Science will be solely responsible for the continued development and commercialization of CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insufficiency (EPI).
Lead Product(s): CDX-7108
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CDX-7108
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Codexis
Deal Size: $50.0 million Upfront Cash: $5.0 million
Deal Type: Agreement December 27, 2023
Details:
QM1114-DP (RelabotulinumtoxinA) is a rapid and long lasting small molecule injection formulation, which is being investigated for dermatological conditions like Crow’s Feet and Frown Lines.
Lead Product(s): RelabotulinumtoxinA
Therapeutic Area: Dermatology Product Name: QM1114-DP
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
Under the termination, Ipsen will retain all rights and obligations related to its early-stage R&D neurotoxin pipeline, including the development of IPN10200 (abobotulinumtoxinA), for the treatment of upper facial lines and muscle spasticity.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: IPN10200
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Ipsen
Deal Size: $41.1 million Upfront Cash: $13.7 million
Deal Type: Termination July 27, 2023
Details:
Vowst (fecal microbiota spores, live-brpk) is approved by FDA as the first orally administered microbiota-based therapeutic for the prevention of recurrent C. difficile infection (CDI).
Lead Product(s): Fecal Microbiota Spores Live-brpk
Therapeutic Area: Infections and Infectious Diseases Product Name: Vowst
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Seres Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
The agreement aimed to jointly commercialize Vowst (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults following antibiotic treatment for recurrent CDI, following its FDA Approval.
Lead Product(s): Fecal Microbiota Spores Live-brpk
Therapeutic Area: Infections and Infectious Diseases Product Name: Vowst
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Seres Therapeutics
Deal Size: $525 million Upfront Cash: $175 million
Deal Type: Agreement May 30, 2023
Details:
TOTUM•63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes. TOTUM•63 benefits from intellectual property validated by patents in the world's leading markets.
Lead Product(s): TOTUM•63
Therapeutic Area: Endocrinology Product Name: TOTUM•63
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Valbiotis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
Vowst (fecal microbiota spores, live-brpk) is approved by FDA as the first orally administered microbiota-based therapeutic for the prevention of recurrent C. difficile infection (CDI).
Lead Product(s): Fecal Microbiota Spores Live-brpk
Therapeutic Area: Infections and Infectious Diseases Product Name: Vowst
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Seres Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
Sculptra is the first and original injectable collagen stimulator containing microparticles of unique poly-L-lactic acid (PLLA-SCA) which gradually revitalizes the skin’s structural foundation.
Lead Product(s): L-Lactic Acid,Sodium Carboxymethylcellulose
Therapeutic Area: Dermatology Product Name: Sculptra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
